When Brian, a forty-three-year-old software engineer in Portland, walked into a ketamine clinic in 2023, he was not expecting the experience to change. He had failed five antidepressants, two rounds of ECT, and was running out of options. The infusion itself took forty minutes. He lay in a dim room with headphones in, listening to a playlist someone had made for him. A therapist checked in via intercom. When it was over, he cried for an hour.
He went back nine times over the following year. Each session included what the clinic called "integration": a structured conversation before and after the infusion. Brian describes the difference as night and day compared to a friend who tried the same clinic without the integration component. His friend's ketamine experiences were, in his words, "a dissociative carnival" with nothing to show for them afterward. Brian is not a scientific control. But his experience points at a question that Massachusetts General Hospital is now trying to answer with the rigor of a clinical trial: does what happens around the ketamine matter as much as the ketamine itself?
MGH announced this month an IRB-approved clinical study evaluating psychedelic coaching as an adjunct to standard care within the hospital's ketamine clinic. The study is running in partnership with the Fireside Project, a psychedelic harm-reduction nonprofit founded in 2020 that has supported more than 33,000 callers through its Psychedelic Support Line, according to a press release from the organization. Dr. Maren Nyer, a psychologist at the MGH Depression Clinical and Research Program and assistant professor at Harvard Medical School, and Dr. Franklin King, a psychiatrist at the MGH Center for the Neuroscience of Psychedelics and an instructor at Harvard Medical School, are co-principal investigators.
The study is testing whether pre-session preparation and post-session integration work, delivered by Fireside-trained coaches, improves depression outcomes over ketamine treatment alone. It is a simple question with an enormous implied stakes. If the MGH trial validates the coaching model, it will not just change ketamine treatment. It will provide the first rigorously collected evidence that "set and setting," the psychological environment surrounding a psychedelic experience, drives therapeutic outcomes across serotonergic psychedelics broadly. That evidence, if it holds, could unlock insurance coverage and FDA pathways for an industry that has operated on anecdote, enthusiasm, and unverified case reports since the first ketamine clinics opened after the FDA approved esketamine (Spravato) for treatment-resistant depression in 2019, as STAT News reported.
Ketamine works fast. A meta-analysis published in Nature Medicine covering fourteen studies and 1,380 participants found a significant reduction in suicidal ideation within the first day after treatment. That speed is its selling point: traditional antidepressants can take weeks to show effect, and patients in acute suicidal crisis do not have weeks. But the duration of that effect is the problem. A study published in Nature Medicine involving 168 adults with treatment-resistant depression found that the highest dose tested, 180 milligrams delivered over twelve weeks, produced significant symptom improvement, but the study design did not isolate what happened when psychological support was added to the pharmacological protocol. The field knows ketamine reduces depression symptoms rapidly. It does not know with confidence how much of that effect is the drug, how much is the context, and how much is some combination that cannot be disentangled without a trial exactly like the one MGH is now running.
The commercial logic for adding coaching is straightforward. Ketamine clinics have proliferated since the FDA approved esketamine (Spravato), a nasal spray containing esketamine, for treatment-resistant depression in 2019. A typical infusion runs $400 to $800 per session, and most patients require multiple sessions. Coaching, if it genuinely extends or deepens the therapeutic window, could mean fewer infusions over time: a cost offset that insurers might actually want to pay for. The harder commercial question is whether "psychedelic coaching" can survive the transition from a wellness-adjacent service to a reimbursable medical intervention. Fireside Project is not a medical device company. Its coaches are not billing under established CPT codes. The path to insurance coverage runs through clinical trial evidence, then a billing-code application, then a coverage determination. The MGH trial is the first step in a very long corridor.
Fireside Project's role in the study goes beyond providing coaches. The organization launched an AI chatbot called Lucy in December 2025, designed to train psychedelic practitioners including in ketamine-assisted psychotherapy scenarios. The chatbot plays the role of a client preparing for or processing a ketamine journey. This is a practical training tool for coaches who are in short supply: the scarcity of trained integration specialists is a real bottleneck in the field. It is also a data-collection mechanism. Every coaching scenario Lucy trains generates structured data about what patients experience, what they need from a coach, and what language helps versus harms. If Fireside Project can show that Lucy-trained coaches produce outcomes comparable to in-person-trained coaches, it dramatically lowers the cost of scaling the model. That is the longer game inside the MGH trial: not just proving the concept, but building the infrastructure to deploy it.
The broader context is the psychedelic medicine revival. After Lykos Therapeutics received a complete response letter from the FDA for its MDMA-assisted PTSD therapy in 2024, citing trial design flaws and concerns about functional unblinding, the field absorbed a humbling lesson about how hard it is to run placebo-controlled trials when the intervention itself produces a conspicuous subjective state. Ketamine is less controversial in this respect because it is already approved and used widely, but the same blinding problem applies: patients who know they received ketamine (rather than a placebo) behave differently in outcome assessments. The MGH trial is attempting to isolate the coaching component, not the ketamine itself, which sidesteps the blinding problem for the primary question but leaves open whether the coaching effect is partly a ritual effect, the benefit of being seen and supported, rather than a specific psychotherapeutic mechanism.
This is the point where the field fractures. Psychedelic researchers generally agree that set and setting matters for classical psychedelics like psilocybin and MDMA, where the subjective experience is considered by many to be a central component of the therapeutic mechanism. Ketamine's pharmacology is different: it acts primarily on glutamate receptors, not serotonin pathways, and produces a dissociative state that some researchers argue is pharmacologically distinct from the "psychedelic experience" most people picture. Whether set and setting contributes to ketamine's antidepressant effects in the same way it does for psilocybin is an open empirical question. The MGH trial will not settle the mechanism debate. What it might settle is whether there is a clinically meaningful difference in depression outcomes when coaching is added. That is a more modest claim than "psychedelic therapy works because of the mystical experience," but it is also a claim that can survive the scrutiny of a randomized trial.
The trial is expected to enroll through 2026 with primary outcomes assessed at twelve weeks. If the results are positive, the next question is whether they replicate and whether the coaching model scales. The field has seen promising early trial results before. What it has not seen is a sustained, multi-site effort to build the evidence base for the support infrastructure around psychedelic medicine. That is the gap the MGH-Fireside partnership is trying to fill. Whether it succeeds or not, the trial itself represents a shift in how the industry is approaching evidence: from hoping the experience is the medicine, to testing whether the support around the experience makes a measurable difference.
